Arcturus Therapeutics (ARCT) AI Stock Analysis

• Market Cap: $242.49M
• Dividend Yield: N/A
• Average Volume (3M): 829.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.33
• Revenue Growth: -41.53%
• EPS Growth: -11.32%
• Country: US
• Employees: 174
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 27,154,530
• 10 Day Avg. Volume: 934,920
• 30 Day Avg. Volume: 829,622
• PEG Ratio: -0.03
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 3.31
• P/FCF Ratio: -7.59
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 1.40
• Enterprise Value/Gross Profit: 1.45
• Enterprise Value/Ebitda: -1.87
• 1Y Price Target: $31.29
• Price Target Upside: 307.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $7.00 ▼(-8.74% Downside)

Arcturus Therapeutics' overall stock score is primarily impacted by its financial performance, which is challenged by declining revenues and persistent losses. Technical analysis indicates a bearish trend, and valuation metrics are poor due to negative earnings. While there are some positive developments in clinical trials and partnerships, these are overshadowed by significant financial and regulatory challenges.

Positive Factors

Partnership with Meiji Seika Pharma

The partnership with Meiji Seika Pharma for the COVID-19 vaccine launch in Japan enhances Arcturus's market presence and revenue potential in Asia, providing a strategic foothold in a significant market.

ARCT032 Phase II Clinical Trial Progress

Positive interim results for ARCT032 in cystic fibrosis indicate promising therapeutic potential, supporting Arcturus's pipeline strength and long-term growth prospects in rare disease treatments.

Financial Position and Cost Reductions

A strong cash position and planned cost reductions provide financial stability, allowing Arcturus to focus on strategic therapeutic programs and navigate market challenges effectively.

Negative Factors

Revenue Decline

Significant revenue decline due to reduced collaboration revenues poses a challenge to financial performance, impacting cash flow and limiting resources for R&D investments.

Indefinite Delay in Costave BLA Filing

The indefinite delay in the BLA filing for Costave affects Arcturus's commercial prospects in the U.S., limiting potential revenue streams from a key market.

Increased Net Loss

Rising net losses reflect operational inefficiencies and financial strain, challenging Arcturus's ability to sustain long-term profitability and invest in growth initiatives.

Arcturus Therapeutics Business Overview & Revenue Model

Company Description

Arcturus Therapeutics is a biopharmaceutical company specializing in the development of innovative RNA medicines, particularly focusing on mRNA technology for the treatment of various diseases. The company operates primarily in the biotechnology sector and is engaged in the research and development of therapeutics targeting significant unmet medical needs, including infectious diseases and rare genetic disorders. Arcturus's core products include its proprietary lipid-mediated delivery system for mRNA and a pipeline of drug candidates for conditions such as COVID-19 and cystic fibrosis.

How the Company Makes Money

Arcturus Therapeutics generates revenue primarily through partnerships and collaborations with other pharmaceutical companies and research institutions, which may involve upfront payments, research funding, and milestone payments as drug candidates progress through clinical trials. Additionally, the company may earn royalties from sales of products developed through such collaborations. Significant partnerships with larger biopharmaceutical firms enhance its financial stability and provide resources necessary for advancing its mRNA technology and clinical programs. Furthermore, government grants and funding for research initiatives can also contribute to its income stream.

Arcturus Therapeutics Financial Statement Overview

Summary

Arcturus Therapeutics faces significant financial challenges, with declining revenues and persistent losses impacting profitability and cash flow. While the balance sheet remains relatively stable with low leverage, the negative cash flow trends and profitability issues pose risks to financial stability.

Income Statement

Arcturus Therapeutics has experienced a significant decline in revenue from 2022 to TTM, with a negative revenue growth rate. The gross profit margin is positive, but the net profit margin is negative due to substantial net losses. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio, indicating manageable leverage. However, the return on equity is negative due to net losses. The equity ratio is strong, suggesting a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

Arcturus Therapeutics has negative free cash flow and operating cash flow, indicating cash burn. The free cash flow growth rate is negative, showing deterioration in cash generation. The ratios of operating and free cash flow to net income are not favorable, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	92.04M	138.39M	157.75M	205.75M	12.36M	9.54M
Gross Profit	88.70M	138.39M	157.75M	205.75M	12.36M	-46.41M
EBITDA	-68.74M	-77.40M	-24.16M	13.70M	-201.66M	-70.64M
Net Income	-66.71M	-80.94M	-29.73M	9.35M	-203.67M	-72.15M
Balance Sheet
Total Assets	282.34M	344.07M	429.40M	450.39M	392.81M	476.46M
Cash, Cash Equivalents and Short-Term Investments	180.36M	237.03M	292.00M	391.88M	370.49M	462.89M
Total Debt	21.86M	28.55M	30.22M	94.75M	69.15M	20.75M
Total Liabilities	57.78M	103.09M	150.89M	180.07M	164.60M	79.90M
Stockholders Equity	224.56M	240.98M	278.51M	270.31M	228.21M	396.55M
Cash Flow
Free Cash Flow	-58.65M	-60.40M	-21.00M	24.27M	-138.45M	-44.60M
Operating Cash Flow	-58.33M	-59.75M	-18.10M	31.99M	-135.04M	-42.86M
Investing Cash Flow	-318.00K	-648.00K	-2.90M	-7.73M	-3.41M	-1.74M
Financing Cash Flow	1.83M	5.42M	-24.09M	-2.86M	48.02M	436.14M

Arcturus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARCT, the sentiment is Negative. The current price of 7.67 is above the 20-day moving average (MA) of 6.82, below the 50-day MA of 11.70, and below the 200-day MA of 13.43, indicating a neutral trend. The MACD of -0.95 indicates Negative momentum. The RSI at 43.27 is Neutral, neither overbought nor oversold. The STOCH value of 83.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARCT.

Arcturus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	78 Outperform	$768.35M	6.68	220.06%	―	79.13%	2798.12%
ARVN	61 Neutral	$841.34M	―	―	―	―	―
CMPX	60 Neutral	$914.21M	―	-37.82%	―	-100.00%	-28.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARCT	46 Neutral	$242.49M	-4.02	-27.43%	―	-41.53%	-11.32%
OLMA	46 Neutral	$2.23B	―	-59.22%	―	―	17.23%
ERAS	34 Underperform	$936.25M	―	-32.00%	―	―	45.66%

Arcturus Therapeutics Corporate Events

Arcturus Therapeutics Announces Phase 2 Trial Results

On October 22, 2025, Arcturus Therapeutics announced interim results from its Phase 2 clinical trial of ARCT-032, an investigational mRNA therapy for cystic fibrosis, marking a significant step in its therapeutic development. Additionally, the company is involved in a legal dispute with AbbVie Inc. and others over trade secrets, and is working with CSL Seqirus on regulatory processes for KOSTAIVE, a self-amplifying mRNA vaccine, facing new FDA requirements for additional data.

Arcturus Therapeutics Partners on New COVID-19 Vaccine Launch

On September 26, 2025, Meiji Seika Pharma Co., Ltd., a subsidiary of Meiji Holdings Co., Ltd., launched KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine in Japan. This vaccine targets the SARS-CoV-2 Omicron sublineage JN.1 variant XEC and has shown efficacy against multiple variants in non-clinical studies. The launch follows a distribution agreement with CSL Seqirus for sales in Japan, marking a significant step in the company’s efforts to combat COVID-19.